Biophytis S.A.
Clinical-stage biotech developing therapeutics for age-related degenerative diseases.
ALBPS | PA
Overview
Corporate Details
- ISIN(s):
- FR0012816825 (+4 more)
- LEI:
- 9695008GIE061NBGU106
- Country:
- France
- Address:
- 14 AVENUE DE L'OPERA, 75001 PARIS
- Website:
- https://www.biophytis.com/en/
Description
Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-01-10 19:31 |
Biophytis announces the issuance of a €3 million tranche of ORNANEBSA
|
English | 187.4 KB | ||
| 2020-01-10 19:31 |
Biophytis annonce l’émission d’une tranche d’ORNANEBSA d’un montant de 3,0M€
|
French | 190.5 KB | ||
| 2020-01-02 18:00 |
Biophytis has appointed Evelyne Nguyen as CFO and Strengthens Senior Management…
|
English | 136.9 KB | ||
| 2020-01-02 18:00 |
Biophytis nomme Evelyne Nguyen au poste de Directrice Administrative et Financi…
|
French | 209.2 KB | ||
| 2019-12-16 08:00 |
Biophytis Receives FDA Approval to Proceed with the MYODA Program for Clinical …
|
English | 176.5 KB | ||
| 2019-12-16 08:00 |
Biophytis reçoit l’accord de la FDA pour démarrer le développement clinique MYO…
|
French | 167.2 KB | ||
| 2019-12-12 18:00 |
Biophytis to attend Biotech Showcase™ 2020 in San Francisco, USA
|
English | 163.4 KB | ||
| 2019-12-12 18:00 |
Biophytis annonce sa participation au Biotech Showcase™ 2020 à San Francisco, E…
|
French | 158.3 KB | ||
| 2019-12-09 08:00 |
Biophytis Presents Preliminary Analysis of SARA-OBS study at the 12th Annual Co…
|
English | 264.4 KB | ||
| 2019-12-09 08:00 |
Biophytis présente une analyse préliminaire de l’étude SARAOBS au 12ème Congrès…
|
French | 184.6 KB | ||
| 2019-12-04 08:00 |
Biophytis to attend 11th Geneva MidCap Event
|
English | 102.5 KB | ||
| 2019-12-04 08:00 |
Biophytis annonce sa participation au MidCap Event à Genève
|
French | 142.1 KB | ||
| 2019-11-18 18:00 |
Biophytis to participate in the 6th China Healthcare Summit organized by BioCen…
|
English | 102.4 KB | ||
| 2019-11-18 18:00 |
Biophytis participe à la conférence annuelle China Healthcare Summit organisée …
|
French | 171.7 KB | ||
| 2019-11-15 08:00 |
Biophytis Files IND Application with FDA for Sarconeos (BIO101) to Support Plan…
|
English | 192.0 KB |
Automate Your Workflow. Get a real-time feed of all Biophytis S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biophytis S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biophytis S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-22 | N/A | Other | Buy | 8,443,190 | 79,365.99 EUR |
| 2020-12-16 | N/A | Other | Sell | 500,000 | 499,000.00 EUR |
| 2020-12-16 | N/A | Other | Other | 313,417 | N/A |
| 2020-04-30 | N/A | Other | Other | 2,955,701 | 177,342.06 EUR |
Peer Companies
